


What is claimed is:

1. A compound represented by formula I,



or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

each W is independently N or CR<sup>1</sup>;

each R<sup>1</sup> is independently selected from -H, halogen, trihaloalkyl, -CN, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>7</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, -R<sup>7</sup>, and -A-R<sup>7</sup>; provided at least one of R<sup>1</sup> is -A-R<sup>7</sup>, wherein, only for said at least one -A-R<sup>7</sup>, R<sup>7</sup> must be an optionally substituted heteroalicyclic ring, and any nitrogen of said optionally substituted heteroalicyclic ring cannot be directly bound to A;

A is O, S(O)<sub>0-2</sub>, and NR<sup>6</sup>;

L is O, S(O)<sub>0-2</sub>, or NR<sup>3</sup>;

Q is C or N, when Q is N, then R<sup>4</sup> does not exist;

R<sup>2</sup> and R<sup>3</sup> are each independently -H or -R<sup>7</sup>;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H, -OR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, halogen, trihalomethyl, and -R<sup>7</sup>; or

R<sup>4</sup> and R<sup>5</sup>, when taken together, form a five or six-membered aromatic ring system containing between zero and two nitrogens, said five or six-membered aromatic ring system optionally substituted with between zero and four of R<sup>15</sup>;


R<sup>6</sup> is selected from -H, optionally substituted C<sub>1-8</sub>alkyl, optionally substituted arylC<sub>1-8</sub>alkyl, optionally substituted heterocyclylC<sub>1-8</sub>alkyl, optionally substituted aryl, and optionally substituted heterocyclyl;

$R^7$  is selected from -H, optionally substituted  $C_{1-8}$ alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heterocyclyl; provided that there are at least two carbons between any heteroatom of  $R^7$  and A or either nitrogen to which  $R^2$  or  $R^3$  are attached; or

$R^6$  and  $R^7$ , when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclic ring, said optionally substituted five- to seven-membered heterocyclic ring optionally containing at least one additional heteroatom selected from nitrogen, oxygen, sulfur, and phosphorus;

$R^8$  is -H, -NO<sub>2</sub>, -CN, -OR<sup>6</sup>, and optionally substituted  $C_{1-8}$ alkyl;

X is selected from one of the following six formulae:



wherein m is zero to five, n is zero to three, and Z is N or CR<sup>10</sup>;

$R^{10}$  is selected from -H, halogen, trihalomethyl, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and R<sup>7</sup>;

K is O, S, or NR<sup>11</sup>;

$R^{11}$  is selected from cyano, -NO<sub>2</sub>, -OR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(O)R<sup>7</sup>, and R<sup>6</sup>; and

each  $R^{15}$  is independently selected from -H, halogen, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and R<sup>7</sup>.

2. The compound according to claim 1, wherein L is NR<sup>3</sup>.

3. The compound according to claim 2, wherein K is either O or NR<sup>11</sup>.


4. The compound according to claim 3, wherein  $R^2$  and  $R^3$  are each independently selected from -H and optionally substituted  $C_{1-8}$ alkyl, wherein substitution on the  $C_{1-8}$ alkyl of optionally substituted  $C_{1-8}$ alkyl is selected from -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, heterocyclic, alicyclic, and aryl.

5. The compound according to claim 4, wherein  $R^2$  and  $R^3$  are -H.

6. The compound according to claim 5, wherein only one of  $R^1$  is -A-R<sup>7</sup>, where A is selected from O, S(O)<sub>0-1</sub>, and NR<sup>6</sup>; and for -A-R<sup>7</sup>, R<sup>7</sup> is an optionally substituted heteroalicyclic ring.


7. The compound according to claim 6, wherein R<sup>6</sup> is selected from -H and  $C_{1-8}$ alkyl, said  $C_{1-8}$ alkyl optionally substituted with one or more groups each independently selected from -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, heterocyclic, alicyclic, and aryl; and R<sup>7</sup> of -A-R<sup>7</sup> is selected from the following optionally substituted heteroalicyclics: azetidine, perhydroazepinyl, piperidinyl, piperazinyl, azabicyclo[3.2.1]octyl, octahydrocyclopenta[c]pyrrole, 2-oxopiperidinyl, 2-oxopyrrolidinyl, pyrrolidinyl, dihydropyridinyl, tetrahydropyridinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, thiamorpholinyl sulfone, and dioxaphospholanyl.

8. The compound according to claim 7, wherein X is



m is 0 to 3, and R<sup>10</sup> is selected from -H, halogen, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and optionally substituted  $C_{1-8}$ alkyl; said  $C_{1-8}$ alkyl optionally substituted with one or more groups each independently selected from -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, heterocyclic, alicyclic, and aryl.

9. The compound according to claim 8, of formula II:




wherein:

A, R<sup>4</sup>, R<sup>5</sup>, R<sup>10</sup>, and m are as defined above;

R<sup>7</sup> is selected from optionally substituted perhydroazepinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, and optionally substituted azetidine; wherein the ring nitrogen of R<sup>7</sup> is substituted with a group R<sup>12</sup>; and

R<sup>12</sup> is selected from -H, optionally substituted C<sub>1-8</sub>alkyl, -SO<sub>2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)R<sup>7</sup>, and an optionally substituted three- or four-carbon bridge between the ring nitrogen of R<sup>7</sup> and a carbon vicinal to the ring nitrogen of R<sup>7</sup>; said three- or four-atom bridge optionally containing an oxygen in substitution for a carbon of the bridge.

10. The compound according to claim 9, wherein -A-R<sup>7</sup> is selected from the following formulae:




wherein R<sup>12</sup> is a C<sub>1-4</sub>alkyl; R<sup>13</sup> is selected from -H, an optionally substituted alkoxy group, an optionally substituted amino group, and an optionally substituted heteroalicyclic, with the proviso that a heteroatom of said optionally substituted alkoxy group, said optionally substituted amino group, or said optionally substituted heteroalicyclic cannot be attached to a carbon of R<sup>12</sup> which is directly attached to the ring nitrogen of R<sup>7</sup>; and R<sup>14</sup> is selected

from -H, halogen, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and optionally substituted C<sub>1-6</sub>alkyl.

11. The compound according to claim 10, wherein A is -NR<sup>6</sup>- where R<sup>6</sup> is selected from -H and C<sub>1-8</sub>alkyl, said C<sub>1-8</sub>alkyl substituted with at least one of -CO<sub>2</sub>H and -CO<sub>2</sub>C<sub>1-8</sub>alkyl.

12. The compound according to claim 11, of formula III.



III

13. The compound according to claim 12, wherein R<sup>12</sup> is a C<sub>2-4</sub>alkyl; R<sup>13</sup> is as defined above; R<sup>10</sup> is selected from -H, halogen, perfluoroalkyl, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -NC(O)R<sup>6</sup>, -NCO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H, halogen, and C<sub>1-4</sub>alkyl; or R<sup>4</sup> and R<sup>5</sup> combined are an optionally substituted phenyl; and m is 0-3.

14. The compound according to claim 13, wherein R<sup>12</sup> is an ethylene; R<sup>10</sup> is halogen; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H, halogen, and C<sub>1-2</sub>alkyl; and m is 1-3.







15. The compound according to claim 14, wherein each R<sup>10</sup> is independently selected from fluorine and chlorine; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H and C<sub>1-2</sub>alkyl; and m is 1-3.

16. The compound according to claim 15, wherein each R<sup>10</sup> is independently selected from fluorine and chlorine; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H and -CH<sub>3</sub>; and m is 1-2.

17. The compound according to claim 16, wherein R<sup>10</sup> is fluorine; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H and -CH<sub>3</sub>; and m is 1.

18. The compound according to claim 1, selected from the following:

Entry	Name	Structure
1	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[[1-(phenylmethyl)pyrrolidin-3-yl]amino]-1,3-dihydro-2H-indol-2-one	
2	(3Z)-5-[(1-ethylpiperidin-3-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl][4-(methoxy)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl][4-methylphenyl]methylidene]-1,3-dihydro-2H-indol-2-one	

7	(3Z)-3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
8	(3Z)-3-[1H-benzimidazol-2-yl(4-(methoxy)phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
9	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
10	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
11	(3Z)-3-[(4-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	







13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-(methyloxy)phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
16	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
17	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
18	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	









19	(3Z)-3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
20	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl}benzonitrile	
21	(3Z)-3-[(3-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
22	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
23	3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl}benzenecarboximide	
24	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

25	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
26	(3Z)-3-[1H-benzimidazol-2-yl[3-(methoxy)phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
27	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
28	2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione	
29	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-[2-(dimethylamino)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
30	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-(methylsulfonyl)piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






31	(3Z)-5-(8-azabicyclo[3.2.1]oct-3-ylamino)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
32	(3Z)-3-[1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
33	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
34	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-(phenylmethyl)piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
35	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
36	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	

37	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}oxy)-1,3-dihydro-2H-indol-2-one	
38	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
39	(3Z)-3-[1H-benzimidazol-2-yl(3-(methyloxy)phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
40	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
41	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
42	(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

43	(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)(methyl)amino]-1,3-dihydro-2H-indol-2-one	
44	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)oxy]-1,3-dihydro-2H-indol-2-one	
45	(3Z)-3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
46	(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
47	(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
48	(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	






49	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
51	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
53	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
54	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	







55	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
56	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
58	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-(trifluoromethyl)phenyl)methylidene]-1,3-dihydro-2H-indol-2-one	

61	(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one	
65	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	









66	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
68	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene]-1,3-dihydro-2H-indol-2-one	
69	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
70	(3Z)-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
71	(3Z)-3-[1H-imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

72	(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
73	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
75	(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	







77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
79	(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one	
82	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-(2-piperidin-1-ylethyl)piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

83	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-morpholin-4-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
84	(3Z)-5-[[1-(2-(diethylamino)ethyl)piperidin-4-yl]amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
85	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
86	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[[1-methylpiperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
87	(3Z)-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-5-[[1-(2-(methyloxy)ethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one	
88	ethyl 2-[(Z)-(3-fluorophenyl)[5-[[1-(2-(methyloxy)ethyl)piperidin-4-yl]amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene]methyl]-4-methyl-1H-imidazole-5-carboxylate	

89	(3Z)-3-[1H-imidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
90	(3Z)-3-{1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
91	(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
92	(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-(methylsulfonyl)piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	
94	(3Z)-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one	

95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
98	(3Z)-3-{1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-[(1-[2-(methyloxy)ethyl]piperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
99	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-1,2,4-triazol-5-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
100	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	

101	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one	
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
103	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
106	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	

107	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
108	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one	
109	(3Z)-3-[(2,3-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
112	(3Z)-3-[(2,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	



113	(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
114	(3Z)-3-[(3-trifluoromethylphenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
115	(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
116	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
117	(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one	

19. A pharmaceutical composition comprising a compound according to any one of claims 1-18 and a pharmaceutically acceptable carrier.
20. A metabolite of the compound or the pharmaceutical composition according to any one of claims 1-19.
21. A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition according to any of claims 1-19.
22. The method according to claim 21, wherein the kinase is at least one of VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta).
23. The method according to claim 22, wherein modulating the *in vivo* activity of the kinase comprises inhibition of said kinase.
24. A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in any one of claims 1-19.
25. A method of screening for modulator of a kinase, the method comprising combining a compound according to any one of paragraphs 1-18, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.
26. A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a composition comprising a compound according to any one of claims 1- 18 to a cell or a plurality of cells.